PDCD1 and non-small cell lung carcinoma: The first in human clinical trial involving CRISPR/Cas9 system was initiated in 2016 to treat advanced non-small cell lung cancer and aimed to knockout the immune checkpoint Programmed cell Death-1 (PD-1) in autologous T-cells (NCT02793856)150,151.